Antibody composition for detecting recombinant varicella-zoster virus glycoprotein e and use thereof
By using the monoclonal antibodies 1M4 and 1M2 combined with an ELISA method, the problems of insufficient sensitivity and repeatability in the detection of recombinant varicella-zoster virus glycoprotein E in existing technologies have been solved, achieving efficient and accurate quality control and detection of gE antigen.
Patent Information
- Application Number
- CN202510591002.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2025-05-08
- Publication Date
- 2025-11-07
- Estimated Expiration
- 2045-05-08
AI Technical Summary
The lack of a highly sensitive and repeatable method for detecting recombinant varicella-zoster virus glycoprotein E in the current technology affects the accuracy and consistency of vaccine quality control.
Monoclonal antibodies 1M4 and 1M2 were used to recognize gE antigen. Combined with ELISA detection, horseradish peroxidase (HRP) was used as a marker. The concentration of gE antigen was detected by coating and enzyme-linked reaction.
It achieves highly sensitive, rapid, and reproducible detection of gE antigen, enabling accurate monitoring of vaccine quality and is suitable for gE antigen concentration detection and quality control during vaccine production.
Smart Images

Figure CN120399046B_ABST
Abstract
Description
TECHNICAL FIELD
[0001] The present application relates to the field of medicine biotechnology, and particularly relates to an antibody composition for detecting recombinant varicella zoster virus glycoprotein E and application thereof. BACKGROUND
[0002] Herpes Zoster (HZ) is a vesicular disease appearing in the skin area, which is caused by the reactivation of varicella-zoster virus latent in the body. The prodromal symptom of HZ is usually pain in the affected skin area, and then vesicular lesions appear in the skin accompanied by pain, which usually lasts until the skin lesions heal.
[0003] The antigen as the active ingredient of the vaccine plays a decisive role in the effect of the vaccine, and the content monitoring of the antigen in the production process, the stock solution, the finished product and the stability sample is particularly important. The same method is used for detection of all samples, which can directly reflect the production process and the stability of each batch, and plays a key role in the quality control of the vaccine.
[0004] Based on this situation, the present application is proposed. SUMMARY
[0005] To solve the problems in the prior art, the present application provides an antibody composition for detecting recombinant varicella zoster virus glycoprotein E and application thereof, which can be used for detecting gE antigen, has high detection sensitivity and good repeatability.
[0006] In order to achieve the purpose of the present application, the following scheme is adopted:
[0007] In a first aspect, the present application provides an antibody composition for detecting recombinant varicella zoster virus glycoprotein E, which is specifically as follows:
[0008] The monoclonal antibody 1M4 has a heavy chain variable region sequence as shown in SEQ ID NO. 1 and a light chain variable region sequence as shown in SEQ ID NO. 2.
[0009] The monoclonal antibody 1M2 has a heavy chain variable region sequence as shown in SEQ ID NO. 3 and a light chain variable region sequence as shown in SEQ ID NO. 4.
[0010] The heavy chain constant region of the monoclonal antibody 1M4 and the monoclonal antibody 1M2 is IgG1 type, and the light chain constant region is κ type.
[0011] In a second aspect, the two monoclonal antibodies of the present application have the following applications:
[0012] (1) Two monoclonal antibodies can recognize different antigen sites on the gE antigen, and are used for detecting the concentration of the gE antigen, and the application is not for the purpose of diagnosing diseases, and the amino acid sequence of the gE antigen is shown as SEQ ID NO. 17.
[0013] (2) For quality control and effect evaluation of vaccines prepared using the gE antigen.
[0014] In a third aspect, the application provides an ELISA detection method using the two monoclonal antibodies, and the method comprises:
[0015] The monoclonal antibody 1M2 is labeled as a secondary antibody, wherein the label is at least one of a dye, an enzyme, an isotope, and a luminescent reagent, such as horseradish peroxidase (HRP), and the use ratio is 1:1000;
[0016] The monoclonal antibody 1M4 is coated on an ELISA plate as a capture antibody, and the coating concentration is 5 μg / ml.
[0017] The detection process involves necessary blocking solution, diluent, termination solution, and color developing reagent, wherein the blocking solution and the diluent are TBST buffer solutions (containing 1% and 0.1% BSA, respectively), and the termination solution is 1M phosphoric acid.
[0018] The application has the following beneficial effects:
[0019] 1. The detection method developed based on the two monoclonal antibodies has the advantages of high sensitivity, fast speed, and strong tolerance for detecting the gE antigen.
[0020] 2. The method can be used alone for detecting the concentration of the gE antigen, and can also be used for quality control of samples in the production process of the gE antigen, gE stock solution, herpes zoster vaccine, and related stability samples, and can efficiently and accurately quantify the content of the gE antigen in the above-mentioned samples, thereby monitoring the quality of the vaccine. BRIEF DESCRIPTION OF DRAWINGS
[0021] Figure 1 A linear regression graph in a linear test is shown. DETAILED DESCRIPTION
[0022] Example 1
[0023] This embodiment provides an antibody composition for detecting recombinant varicella zoster virus glycoprotein E, which comprises two monoclonal antibodies.
[0024] The monoclonal antibody 1M4 has a heavy chain variable region sequence as shown in SEQ ID NO. 1 and a light chain variable region sequence as shown in SEQ ID NO. 2.
[0025] Monoclonal antibody 1M2, the heavy chain variable region sequence of which is as shown in SEQ ID NO. 3, and the light chain variable region sequence of which is as shown in SEQ ID NO. 4.
[0026] The amino acid sequence of SEQ ID NO. 1:
[0027] EVKLLEAGGGLVQPGGSLKLSCAASGFDFSRYWMNWVRQAPGKGLEWIGEINPDSTMINYTPSLKDKFIISRDNAKNTLYLQMSKVTSEDTALYYCAREMIGNYGMDYWGQGTSVTVSS.
[0028] The amino acid sequence of SEQ ID NO. 2:
[0029] DIVLTQSPASLAVSLGQRATISCKASQSVDYDGDSYMNWYQQKPGQPPKLLIYAASNLESGIPPRFSGSGSGTDFTLNIHPVEEEDAATYYCQQSNEDPFTFGSGTKLEIK.
[0030] The amino acid sequence of SEQ ID NO. 3:
[0031] KVQLQQSGTGLVKPGASVKLSCKASDYTFTDYIIYWVKQRSGQGLEWIGWIYPGTNNIKYNEKFKDKATLTADKSSSTVYMELSRLTSEDSAVYFCARHEDRGYGNYVWFAYWGQGTLVSVSA.
[0032] The amino acid sequence of SEQ ID NO. 4:
[0033] DIQMTQTTSSLSASLGDRVTISCRSSQDIRNYLNWYQQKPDGTVKLLIYYSSRLHSGVPSRFSGSGSGTDFSLTISNLEQGDVATYFCQQGDILPWTFGGGTKLEIK.
[0034] The present application discloses for the first time the amino acid sequences of the above-mentioned complementarity determining regions (CDRs), which novel sequences can impart to the antibody the ability to specifically bind to the gE antigen or protein.
[0035] The heavy chain complementarity determining regions of monoclonal antibody 1M4 comprise CDR-H1, CDR-H2 and CDR-H3, the amino acid sequences of which are shown in SEQ ID NO. 5, SEQ ID NO. 6 and SEQ ID NO. 7, respectively; the light chain complementarity determining regions of monoclonal antibody 1M4 comprise CDR-L1, CDR-L2 and CDR-L3, the amino acid sequences of which are shown in SEQ ID NO. 8, SEQ ID NO. 9 and SEQ ID NO. 10, respectively.
[0036] The heavy chain complementarity determining regions of monoclonal antibody 1M2 comprise CDR-H1, CDR-H2 and CDR-H3, the amino acid sequences of which are shown in SEQ ID NO. 11, SEQ ID NO. 112 and SEQ ID NO. 13, respectively; the light chain complementarity determining regions of monoclonal antibody 1M2 comprise CDR-L1, CDR-L2 and CDR-L3, the amino acid sequences of which are shown in SEQ ID NO. 14, SEQ ID NO. 15 and SEQ ID NO. 16, respectively.
[0037] The heavy chain complementarity determining regions of 1M4:
[0038] CDR-H1, the sequence of SEQ ID NO: 5 is: RYWMN;
[0039] CDR-H2, the sequence of SEQ ID NO: 6 is: EINPDSTMINYTPSLKD;
[0040] CDR-H3, the sequence of SEQ ID NO: 7 is: EMIGNYGMDY.
[0041] The light chain complementarity determining regions of 1M4:
[0042] CDR-H1, the sequence of SEQ ID NO: 8 is: KASQSVDYDGDSYMN;
[0043] CDR-H1, the sequence of SEQ ID NO: 9 is: AASNLES;
[0044] CDR-H1, the sequence of SEQ ID NO: 10 is: QQSNEDPFT.
[0045] The heavy chain complementarity determining regions of 1M2:
[0046] CDR-H1, the sequence of SEQ ID NO: 11 is: DYIIY;
[0047] CDR-H2, the sequence of SEQ ID NO: 12 is: WIYPGTNNIKYNEKFKD;
[0048] The sequence of CDR-H3, SEQ ID NO: 13 is: HEDRGYGNYVWFAY.
[0049] Light chain complementarity determining regions of 1M2:
[0050] The sequence of CDR-H1, SEQ ID NO: 14 is: RSSQDIRNYLN;
[0051] The sequence of CDR-H1, SEQ ID NO: 15 is: YSSRLHS;
[0052] The sequence of CDR-H1, SEQ ID NO: 16 is: QQGDILPWT.
[0053] The heavy chain constant region of monoclonal antibody 1M4 and monoclonal antibody 1M2 is selected from the heavy chain constant region of IgG1, the light chain constant region is selected from the kappa type light chain constant region, and the constant region is of murine origin.
[0054] Example 2
[0055] The two monoclonal antibodies provided in Example 1 have at least the following applications:
[0056] (1) for detecting the concentration of gE antigen, and the application is not for the purpose of diagnosis of disease, and the amino acid sequence of gE antigen is shown as SEQ ID NO. 17;
[0057] (2) for quality control and effect evaluation of vaccines prepared using gE antigen.
[0058] Example 3
[0059] Based on the two monoclonal antibodies of Example 1, this Example 3 provides an ELISA detection method, comprising the following steps:
[0060] The monoclonal antibody 1M4 is diluted to 5 μg / ml for coating, 100 μl / well, and coated overnight at 2-8 DEG C, and the coating solution is carbonate buffer (pH 9.6); after washing 3 times with 250 μl / well of washing solution, 200 μl / well of blocking solution is added for blocking for 1-1.5 hours, and the blocking solution is TBST buffer (containing 1% BSA); the standard, control, quality control and sample are diluted to an appropriate dilution and added in 100 μl / well, and the dilution solution is TBST buffer (containing 0.1% BSA) and incubated at room temperature for 1.75-2.25 hours; after incubation, washing is performed 3 times, and 100 μl / well of horseradish peroxidase (HRP) 1:1000 diluted monoclonal antibody 1M2 is added and incubated for 0.75-1.25 hours; after washing 5 times, 100 μl / well of color developing solution is added, and incubated for 15 minutes in the dark; 100 μl / well of stop solution is added, and the stop solution is 1M phosphoric acid; the determination wavelength is 450 nm, and the reference wavelength is 630 nm for reading. The above tests are all completed at room temperature.
[0061] The detection method provided by the application has good detection precision for gE antigen or protein. Verification data show that in a wide concentration range (as low as medium-high concentration), good detection precision (intra-batch CV < 5%) is achieved, and the intermediate precision verification of different operators and experimental days meets the standard requirements (total CV < 15%), and the detection accuracy recovery rate is 90%-105%. The standard curve (four-parameter curve) has a typical regression coefficient R² ≥ 0.99, shows good linear characteristics in the detection range, the linear regression R² ≥ 0.99 and the batch-to-batch variation coefficient CV% < 10%, the linear range stably covers 2 orders of magnitude, and all the verification indexes meet the standard.
[0062] The features and performances of the application are further described in detail below.
[0063] Example 4
[0064] The embodiment provides a preparation method of a monoclonal antibody, and specifically includes the following steps:
[0065] (1) Mouse immunization: female BALB / c mice are selected, and gE antigen (the amino acid sequence is shown as SEQ ID NO: 17) is emulsified with complete Freund's adjuvant (CFA) (Sigma, St. Louis, MO) for subcutaneous immunization, and after two weeks, the same antigen is emulsified with incomplete Freund's adjuvant for continuous immunization for 2 injections with an interval of 2 weeks. After 4 immunizations, an interval of 1 month is arranged for fusion, and finally, the spleen is immunized with the same antigen diluted with PBS for the last boost.
[0066] (2) Cell fusion and screening: mouse spleen cells and mouse myeloma cells SP2 / 0 cells were fused at a ratio of 5:1 using 50% PEG, and were suspended in 1% HAT selection medium for culture. The medium of the fusion plate was changed after 4 days, and the growth of the cloned cells was observed after 7-10 days.
[0067] (3) Hybridoma cell line screening: cell lines that react or do not react with gE antigen were screened by indirect ELISA (using gE antigen coating). Positive wells were repeatedly cloned by limiting dilution to obtain stable hybridoma cells.
[0068] (4) Production of monoclonal antibodies: hybridoma cells that can stably secrete anti-custom antigen were injected into the peritoneal cavity of BALB / c mice pretreated with liquid paraffin oil for in vivo ascites production. Staphylococcal protein A affinity purification of ascites was used to obtain monoclonal antibodies (1M2 and 1M4).
[0069] (5) Hybridoma cell sequencing / variable region gene sequencing: total RNA was extracted from hybridoma cells (1M2 and 1M4), and reverse transcription-polymerase chain reaction (RT-PCR) was performed using 3' RACE (rapid amplification of cDNA ends) and 5' RACE techniques to amplify the first-strand cDNA complementary to the full-length mRNA. Using this cDNA as a template, PCR amplification was performed by designing specific primers to isolate the antibody heavy chain variable region (VH) and light chain variable region (VL) gene fragments. The amplified products were cloned into a TA vector and transformed into competent cells, and positive recombinant clones were selected and verified by sequencing. The gene sequences of the antibody variable regions were finally confirmed by bioinformatics analysis (such as IgBLAST).
[0070] Example 5
[0071] This example provides a sandwich ELISA detection method, which comprises a high adsorption polystyrene microwell plate, a coating solution, a washing solution, a blocking solution, a dilution solution, a TMB developing solution, a termination solution, a coating antibody (1M4), and a secondary antibody (1M2).
[0072] (1) Monoclonal antibody 1M2 labeling
[0073] 1) Remove amino substances from monoclonal antibody 1M2;
[0074] 2) Mix monoclonal antibody 1M2 with pre-activated HRP at a mass ratio of 1:1;
[0075] 3) Add HRP labeling initiator (1.8 μl initiator per 10 μl (monoclonal antibody 1M2 and HRP mixture)), mix well, and then couple at 30-37°C for 2-3 hours in the dark or at 2-8°C for 24 hours.
[0076] 4) Add the labeled termination solution (50 μl per 1 mg of HRP) and mix well, and let stand at room temperature for 1 h;
[0077] 5) Add the preservative solution of the label at a volume ratio of 1:1, mix well, and reserve for use.
[0078] (2) The detection method parameters are as follows:
[0079] Table 1 Instrument and equipment table
[0080]
[0081] The reagents involved are as follows:
[0082] Coating solution (carbonate buffer solution), 10x: weigh 14.35 g of sodium carbonate and 30.68 g of sodium bicarbonate, dissolve in 1 L of ultrapure water, and adjust the pH value to 9.6 ± 0.1 with NaOH solution, and store at 2-8°C for standby.
[0083] Coating solution (carbonate buffer solution), 1x: take 100 ml of 10x carbonate buffer solution, add 900 ml of ultrapure water, mix well, and store at 2-8°C for standby.
[0084] Washing solution (PBST buffer solution): take 1 bag of PBS-T instant granules and add 1 L of ultrapure water, mix well, and stand at room temperature for standby.
[0085] 10% BSA solution: weigh 10 g of BSA, dissolve in 80 ml of water, add water to 100 ml, filter with a 0.22 μm membrane, and store at 2-8°C for standby.
[0086] Blocking solution: take 1 bag of TBS instant granules, add 800 ml of ultrapure water, completely dissolve, mix with 100 ml of 10% BSA, add water to 1 L, and store at 2-8°C; or take 1 bag of TBS-T instant granules, add 800 ml of ultrapure water, completely dissolve, mix with 100 ml of 10% BSA, add water to 1 L, and store at 2-8°C.
[0087] Dilution solution: take 1 bag of TBS instant granules, add 900 ml of ultrapure water, completely dissolve, add 0.5 ml of Tween-20, mix with 10 ml of 10% BSA, add water to 1 L, and store at 2-8°C; or take 1 bag of TBS-T instant granules, add 800 ml of ultrapure water, completely dissolve, mix with 10 ml of 10% BSA, add water to 1 L, and store at 2-8°C.
[0088] Termination solution (1 M phosphoric acid): 67.5 ml of concentrated phosphoric acid, add water to 1000 ml, mix well, and stand at room temperature for standby.
[0089] Specific experimental steps:
[0090] 1) Coating antibody (1M4) is diluted to 5ug / ml, 100ul / well, coated overnight at 2~8℃;
[0091] 2) After washing with 250ul / well for 3 times, add blocking solution 200ul / well, block for 1h~1.5h;
[0092] 3) After diluting the standard, control, quality control and test sample to the appropriate dilution, add 100ul / well, incubate at room temperature for 1.75~2.25h; After incubation, wash for 3 times;
[0093] 4) After diluting the enzyme-labeled secondary antibody (HRP-1M2) to 1:1000, add 100ul / well, incubate for 0.75~1.25h;
[0094] 5) After washing for 5 times, add 100ul / well of color developing solution, avoid light incubation for 15min; Add 100ul / well of stop solution; Measure at 450nm / 630nm.
[0095] Experimental calculation:
[0096] Take the concentration of gE standard as the X axis and the absorbance value as the Y axis, and perform four-parameter fitting. The four-parameter curve R 2 should be ≥0.99; The absorbance value of the blank control should be ≤0.2.
[0097] The measured value of the test sample gE antigen content is obtained by substituting the test sample absorbance value into the four-parameter curve. The relative standard deviation of the measured content between adjacent dilution multiples of the test sample should be ≤10%.
[0098] (3) Methodology verification
[0099] Experiment 1
[0100] The detection method provided in Example 5 was tested for specificity.
[0101] According to the experimental steps of Example 5, the sample without gE antigen and the sample containing gE antigen were determined. The sample without gE antigen was not detected, and the specificity met the requirements.
[0102] Experiment 2
[0103] The detection method provided in Example 5 was tested for accuracy.
[0104] Take the test sample (i.e. the sample to be tested) in Example 5 and dilute it to 10ng / ml with diluent. Then mix it with 10, 20 and 40ng / ml of gE antigen at a ratio of 1:1 to prepare high, medium and low concentration spiked samples. Then follow the experimental steps in Example 5 to test and calculate the recovery rate. The test data are shown in Table 2:
[0105] Table 2. Measured values of test sample solutions
[0106]
[0107] The recovery rates of the high, medium and low concentrations were all between 90% and 105%, indicating that the method provided in Example 5 has good accuracy.
[0108] Experiment 3
[0109] The detection method provided in Example 5 was tested for precision (repeatability).
[0110] The test sample (i.e. the sample to be tested) in Example 5 was taken, and 6 samples were prepared in parallel, and detection and result calculation were performed according to the experimental steps in Example 5. The detection data are shown in Table 3:
[0111] Table 3. Repeatability detection data of test sample
[0112]
[0113] The relative standard deviation of the concentrations of the 6 test sample solutions was 3.6%, which was less than 5%, indicating that the method provided in Example 5 has good repeatability.
[0114] Experiment 4
[0115] The detection method provided in Example 5 was tested for precision (intermediate precision).
[0116] Different experimenters took the test sample (i.e. the sample to be tested) in Example 5, and 6 samples were prepared in parallel, respectively, and detection and result calculation were performed according to the experimental steps in Example 5. The detection data are shown in Table 4:
[0117] Table 4. Intermediate precision detection data of test sample
[0118]
[0119] The relative standard deviation of the concentrations of the 12 test sample solutions between different experimenters was 8.4%, which was less than 10%, indicating that the method provided in Example 5 has good intermediate precision.
[0120] Experiment 5
[0121] The detection method provided in Example 5 was tested for linearity.
[0122] Take the test sample (i.e. the sample to be tested) in Example 5, dilute to 80 ng / ml, 40 ng / ml, 20 ng / ml, 10 ng / ml, 5 ng / ml, 2.5 ng / ml, 1.25 ng / ml, 0.625 ng / ml, as the test sample, the test sample is 3 parallel, test repeated 2 times. The logarithm of the theoretical concentration (abscissa) is plotted against the logarithm of the measured concentration (ordinate), and linear regression is performed using the least squares method. And calculate the correlation coefficient (R 2 ).
[0123] The test sample is set up in 3 parallel samples, double-blind test, the linear regression equation of 6 test data is Y = 0.9966X-0.0429, R 2 = 0.9914, as shown in Figure 1 . It is shown that the method provided in Example 5 is linear in the range of 0.625 ng / ml to 80 ng / ml. According to the accuracy, repeatability, intermediate precision data, the detection range is confirmed to be 1.25 ng / ml to 40 ng / ml.
[0124] Experiment 7
[0125] The detection method provided in Example 5 is tested for durability
[0126] According to the experimental steps in Example 5, adjust the composition of the blocking solution and the diluent, the blocking time, the antigen incubation time, and the enzyme-labeled secondary antibody incubation time, then follow the experimental steps in Example 5 to detect and calculate the results. The detection data are shown in Tables 5 and 6:
[0127] Table 5 Measured data of different blocking solutions and diluents
[0128]
[0129] Table 6 Measured data of different incubation times
[0130]
[0131] According to the experimental steps in Example 5, under different durability experimental conditions, the test sample is detected according to the experimental steps in Example 5. The relative standard deviation between different durability conditions is less than 10%, indicating that the method provided in Example 5 has good durability.
[0132] (4) Method application
[0133] Using the method in Example 5, the gE protein culture supernatant, purified intermediate sample, gE protein stock solution, etc. can be detected to obtain accurate results. The specific detection data are shown in Tables 7-10.
[0134] Table 7 Detection data of gE protein culture supernatant
[0135]
[0136] Table 8 Purification intermediate sample and gE protein bulk testing data
[0137]
[0138] Table 9 Finished product testing data
[0139]
[0140] Table 10 gE protein bulk long-term stability sample testing data
[0141]
[0142] The above examples are only used to illustrate the technical ideas and characteristics of the present application, and do not represent the only or limiting the present application. Those skilled in the art should understand that various changes or equivalent replacements made to the present application without departing from the scope of the present application, all belong to the scope of protection of the present application.
Claims
1. An antibody composition for detecting recombinant varicella zoster virus glycoprotein E, characterized in that, Comprising: monoclonal antibody 1M4, the sequence of the heavy chain variable region of which is shown as SEQ ID NO. 1, and the sequence of the light chain variable region of which is shown as SEQ ID NO. 2; monoclonal antibody 1M2, the sequence of the heavy chain variable region of which is shown as SEQ ID NO. 3, and the sequence of the light chain variable region of which is shown as SEQ ID NO.
4.
2. The antibody composition of claim 1, wherein the recombinant varicella zoster virus glycoprotein E is detected. The heavy chain constant region of monoclonal antibody 1M4 and monoclonal antibody 1M2 is of IgG1 type, and the light chain constant region is of κ type.
3. The antibody composition of claim 2, wherein the recombinant varicella zoster virus glycoprotein E is detected by an enzyme-linked immunosorbent assay (ELISA). The species origin of the constant region is murine.
4. Use of the antibody composition for detecting recombinant varicella zoster virus glycoprotein E according to any one of claims 1 to 3, characterized in that, For detecting the concentration of gE antigen, and the application is not for the purpose of diagnosis of disease, the amino acid sequence of gE antigen is shown as SEQ ID NO.
17.
5. Use of the antibody composition for detecting recombinant varicella zoster virus glycoprotein E according to any one of claims 1 to 3, characterized in that, For quality control and effect evaluation of vaccines prepared using gE antigen, the amino acid sequence of gE antigen is shown as SEQ ID NO. 17.
Citation Information
Patent Citations
Monoclonal antibody for detecting recombinant varicella-zoster virus glycoprotein E (gE) and application thereof
CN116041488A
Varicella-zoster virus recombinant fusion protein and application thereof
CN116731210A
